2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Burkitt Lymphoma
3
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms
1
Lymphoproliferative Disorders
1
Hemostatic Disorders
1
Hematologic Diseases
1
Interventions
Cyclophosphamide
155
Dexamethasone
141
Rituximab
85
fludarabine
80
Lenalidomide
72
Cytarabine
70
Bortezomib
65
fludarabine phosphate
63
Gemcitabine
62
venetoclax
55
pomalidomide
53
Etoposide
53
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
epratuzumab
×
Clear all
NCT01279707
2014-07-14
MARALL
Queen Mary University of London
Phase 1/2
Unknown
55 enrolled